Literature DB >> 12449343

The role of the androgen receptor in prostate cancer.

Haojie Huang1, Donald J Tindall.   

Abstract

Androgens are important not only for the development and function of the normal prostate gland, but also for the maintenance of prostate cancer (PCa) cells. The biological function of androgens is exerted by activation of the transcriptional activity of the androgen receptor (AR). The function of the AR in the prostate is largely dependent on AR protein levels and structural integrity of the protein and other transcription activation factors. Based upon the clinical findings that androgen ablation therapy-resistant PCa still expresses AR and the androgen-regulated gene, prostate-specific antigen, a concept is developing that the androgen receptor iscritical for androgen-refractory prostate cancer cells. Indeed, because of the alterations detected in the AR gene, many noncognate activators, including estrogen, progesterone, peptide growth factors, and cytokines, are able to induce transactivation of the AR under androgen-depleted conditions. Also, transactivational activity of the AR is often modulated by crosstalk between the AR and other signaling pathways in cancerous prostatic cells. Dysregulation of AR function in prostate cancer results in an abnormal profile of AR-regulated genes, which include cell cycle regulators, transcription factors, and those proteins important for cell survival, lipogenesis, and secretion. Thus in this review we will evaluate the significance of the AR in the development and progression of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12449343     DOI: 10.1615/critreveukaryotgeneexpr.v12.i3.30

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  27 in total

1.  Androgen-responsive gene database: integrated knowledge on androgen-responsive genes.

Authors:  Mei Jiang; Yunsheng Ma; Congcong Chen; Xuping Fu; Shu Yang; Xia Li; Guohua Yu; Yumin Mao; Yi Xie; Yao Li
Journal:  Mol Endocrinol       Date:  2009-09-17

2.  Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells.

Authors:  Jin T E Lim; Mahesh Mansukhani; I Bernard Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-24       Impact factor: 11.205

3.  Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy.

Authors:  Tong Sun; Gwo-Shu Mary Lee; Lillian Werner; Mark Pomerantz; William K Oh; Philip W Kantoff; Matthew L Freedman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07       Impact factor: 4.254

4.  Simian virus 40 small t antigen mediates conformation-dependent transfer of protein phosphatase 2A onto the androgen receptor.

Authors:  Chun-Song Yang; Michael J Vitto; Scott A Busby; Benjamin A Garcia; Cristina T Kesler; Daniel Gioeli; Jeffrey Shabanowitz; Donald F Hunt; Kathleen Rundell; David L Brautigan; Bryce M Paschal
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

5.  FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.

Authors:  Laura R Bohrer; Ping Liu; Jian Zhong; Yunqian Pan; James Angstman; Lucas J Brand; Scott M Dehm; Haojie Huang
Journal:  Prostate       Date:  2013-02-06       Impact factor: 4.104

6.  Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer.

Authors:  Yi Peng; Fei Chen; Jonathan Melamed; Luis Chiriboga; Jianjun Wei; Xiangtian Kong; Maureen McLeod; Yirong Li; Caihong X Li; Alice Feng; Michael J Garabedian; Zhengxin Wang; Robert G Roeder; Peng Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-20       Impact factor: 11.205

7.  Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo.

Authors:  Thomas T Y Wang; Tamaro S Hudson; Tien-Chung Wang; Connie M Remsberg; Neal M Davies; Yoko Takahashi; Young S Kim; Harold Seifried; Bryan T Vinyard; Susan N Perkins; Stephen D Hursting
Journal:  Carcinogenesis       Date:  2008-06-26       Impact factor: 4.944

8.  Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.

Authors:  Thomas Nelius; Stephanie Filleur; Alexander Yemelyanov; Irina Budunova; E Shroff; Yelena Mirochnik; Arin Aurora; Dorina Veliceasa; Wuhan Xiao; Zhou Wang; Olga V Volpert
Journal:  Int J Cancer       Date:  2007-09-01       Impact factor: 7.396

9.  Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.

Authors:  Leah S Lyons; Shuyun Rao; Wayne Balkan; Joanne Faysal; Carol A Maiorino; Kerry L Burnstein
Journal:  Mol Endocrinol       Date:  2007-12-13

10.  Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents.

Authors:  Jian Yang; Shuo Wei; Da-Sheng Wang; Yu-Chieh Wang; Samuel K Kulp; Ching-Shih Chen
Journal:  J Med Chem       Date:  2008-03-13       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.